In a patient with lobar pneumonia treated with IV ceftriaxone, paracetamol, and tramadol who is now clinically stable but has thrombocytopenia (platelet count 70 ×10⁹/L), which medication should be discontinued?

Discontinue Tramadol

In a patient with lobar pneumonia who has stabilized after one day of treatment but has thrombocytopenia (platelet count 70 ×10⁹/L), tramadol should be discontinued as it is no longer essential for pain management in a clinically stable patient, while ceftriaxone must be continued to complete the pneumonia treatment course.

Rationale for Each Medication

Ceftriaxone (Option C) - MUST CONTINUE

• Ceftriaxone is the definitive treatment for lobar pneumonia and cannot be stopped after only one day 1, 2
• Guidelines consistently recommend continuing antibiotics for at least 4-14 days depending on clinical response, with a minimum of 2 days after fever resolution 1, 3
• The usual duration for community-acquired pneumonia is 7-10 days, and stopping after one day would lead to treatment failure 4
• While ceftriaxone can rarely cause drug-induced immune thrombocytopenia (DITP), this typically occurs after 5-10 days of therapy, not after one day 5, 6, 7
• The patient's platelet count of 70 ×10⁹/L, while low, is not critically low (>50 ×10⁹/L is generally safe for most procedures), and the temporal relationship makes ceftriaxone an unlikely culprit after just one day

Paracetamol (Option A) - CONTINUE FOR NOW

• Paracetamol is used for fever and pain control in pneumonia
• While the patient is "stable," fever may recur, and symptomatic relief remains beneficial
• Paracetamol does not cause thrombocytopenia
• Can be discontinued once fever has been absent for 24-48 hours 1

Tramadol (Option B) - DISCONTINUE

• Tramadol was initiated for pain control (likely pleuritic chest pain from pneumonia)
• In a patient who has become "stable and improved" after one day, the acute severe pain has likely resolved
• Tramadol does not treat the underlying infection and is purely symptomatic
• Tramadol carries risks of respiratory depression, particularly concerning in a patient with pneumonia and SpO2 of 88%
• This is the only medication that can be safely stopped without compromising pneumonia treatment
• Pain can be managed with paracetamol alone or as-needed basis if it recurs

Azithromycin (Option D) - NOT PRESCRIBED

• This medication was not part of the initial treatment regimen, so this option is irrelevant

Key Clinical Considerations

Regarding the thrombocytopenia (platelet 70 ×10⁹/L):

• This level of thrombocytopenia after one day of ceftriaxone is unlikely to be drug-induced, as DITP typically develops after 5-10 days of exposure 5, 7
• The thrombocytopenia may be related to the sepsis/infection itself rather than medication
• Platelet count of 70 ×10⁹/L does not require immediate intervention unless there is active bleeding
• If thrombocytopenia worsens significantly or drops below 20-30 ×10⁹/L, then drug-induced causes should be reconsidered

Critical pitfall to avoid: Do not stop ceftriaxone prematurely. One day of clinical stability does not indicate completion of pneumonia treatment. Guidelines are clear that antibiotics should continue for at least 2 days after clinical stability is achieved, and typically 7-10 days total 1, 4, 8.